DoD Peer Reviewed Medical Research Program (PRMRP)

Mitochondrial Disease is one of 52 FY26 PRMRP topic areas designated by Congress as military health priorities, so Barth syndrome qualifies on topic. Applications must still argue military health relevance.

Academic, industry, government, and military investigators worldwide — no citizenship restriction. Applications must address a listed topic area (Mitochondrial Disease) and include a one-page Military Relevance Statement.

Two-step process: pre-application via eBRAP, then full application via Grants.gov. FY26 pre-applications closed Jul 23, 2026 (Clinical Trial Award full applications due Sept 22, 2026 for those with pre-applications in); the FY27 cycle is expected ~summer 2027, assuming mitochondrial disease remains a topic area. Applications must include a one-page Military Relevance Statement covering disease prevalence in service members, veterans, and beneficiaries, and dual-use benefit — how the knowledge gained serves both civilian and military needs. Relevant facts for BTHS: military families are TRICARE beneficiaries and affected boys are covered dependants (the Exceptional Family Member Program covers this population); and Barth syndrome is a human model of isolated cardiolipin deficiency, so findings bear on mitochondrial dysfunction in blast injury and TBI (Brain Injury Impact on Cardiac Health is a separate FY26 topic area), Gulf War Illness, exertional rhabdomyolysis and heat illness, and ischemia-reperfusion after hemorrhage. Elamipretide was studied in ischemia-reperfusion before Barth syndrome.

/grants/dod-peer-reviewed-medical-research-program-prmrp/

Copy link